Skip to main content
SearchLogin or Signup

Reviews of "SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination"

Reviewers: Erik Boehm (Hopitaux Universitaires Geneve) | 📗📗📗📗◻️ • Pragya Yadav (National Institute of Virology), Sanjay Kumar ( Armed Forces Medical College) | 📗📗📗📗◻️

Published onSep 15, 2021
Reviews of "SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination"

To read the original manuscript, click the link above.

Summary of Reviews: This preprint claims that the B.1.617 variant displays resistance to Bamlanivimab and a higher degree of immune escape to antibodies induced by either vaccination or prior infection. Reviewers found it timely but in need of minor revisions to make it more specific to B.1.617.2.

Reviewer 1 (Erik Boehm) | 📗📗📗📗◻️

Reviewer 2 (Pragya Yadav, Sanjay Kumar) | 📗📗📗📗◻️

RR:C19 Strength of Evidence Scale Key

📕 ◻️◻️◻️◻️ = Misleading

📙📙 ◻️◻️◻️ = Not Informative

📒📒📒 ◻️◻️ = Potentially Informative

📗📗📗📗◻️ = Reliable

📘📘📘📘📘 = Strong

To read the reviews, click the links below.




Comments
0
comment

No comments here